Market Cap€52m

Last Close €0.56

Onxeo’s proprietary platON platform is based on a unique decoy technology in the field of DNA damage repair inhibition. The compounds have been shown in preclinical studies to be synergistic with DNA breaking therapies and have an ability to reverse tumour resistance to PARP inhibitors and TKIs.

More Onxeo content >

Investment summary

Onxeo’s portfolio focuses on its novel platON platform with AsiDNA as the lead drug candidate. AsiDNA is the only oligonucleotide decoy agonist in development that disrupts and exhausts the tumour DNA damage response mechanism. To date, the only approved similar class of drugs are four commercially successful PARP inhibitors. AsiDNA is now being tested in the Phase Ib part of the DRIIV-1 trial in patients with advanced solid tumours in combination with chemotherapy (the latest interim update in November 2020 showed promising data). Another key Phase Ib/II trial, REVOCAN, is recruiting patients and will evaluate AsiDNA’s potentially unique ability to reverse tumour resistance to the PARP inhibitor, niraparib. The outcomes of all these events will define AsiDNA’s mid- to late-stage development. In January, Onxeo secured a €5m state guaranteed loan extending its cash runway to Q322. In April, Onxeo raised a further €9.7m and revealed a new Phase II trial with AsiDNA in combination with chemotherapy in NSCLC to start in 2021.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2018A 6.1 (3.4) (4.2) 4.92 11.4 N/A
2019A 4.3 (9.1) (11.5) (14.98) N/A N/A
2020E 1.1 1.0 0.4 (0.62) N/A N/A
2021E 0.0 (10.1) (10.8) (13.78) N/A N/A
Industry outlook

Approval of the first PARP inhibitors has kick-started interest by the scientific community and large pharma in the DNA damage response field. Few biotechs are already positioned in this emerging field that has broad potential.

Last updated on 22/09/2021
Content on Onxeo
Onxeo – Edison Open House interview
Healthcare | Edison TV | 3 February 2021
Onxeo – executive interview
Healthcare | Edison TV | 15 December 2020
Onxeo – Progress with both REVOCAN and DRIIV-1b trials
Healthcare | Update | 18 November 2020
View more
Register to receive research on Onxeo as it is published
Share price graph
Balance sheet
Forecast net cash (€m) 10.3
Forecast gearing ratio (%) N/A
Price performance
Actual (3.4) (14.2) (16.8)
Relative* (2.5) (13.7) (38.5)
52-week high/low €0.8/€0.6
*% relative to local index
Key management
Judith Greciet CEO
Nicolas Fellmann CFO
Valérie Leroy Director, Investor Relations & Corporate Com